A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

NCT00630058 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: MP-424(H), PEG-IFN-a-2b, RBV
DRUG: MP-424 (L), PEG-IFN-a-2b, RBV

Sponsor

Tanabe Pharma Corporation

Collaborators

[object Object]